Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis (Q40588563)

21 September 2017

Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis (English)

1 reference

21 September 2017

0 references

Oyama Y

1

1 reference

21 September 2017

Cohen B

2

1 reference

21 September 2017

Traynor A

3

1 reference

21 September 2017

Brush M

4

1 reference

21 September 2017

Rodriguez J

5

1 reference

21 September 2017

Burt RK

6

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

Bone Marrow Transplantation

21 September 2017

1 reference

21 September 2017

29

1 reference

21 September 2017

1

1 reference

21 September 2017

81-85

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703324

21 September 2017

0 references

cites work

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Cause of death in patients attending multiple sclerosis clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Stem cell transplantation in experimental models of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Syngeneic bone marrow transplantation eliminates V beta 8.2 T lymphocytes from the spinal cord of Lewis rats with experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Major morbidity related to hyperthermia in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Fever and evoked potentials in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Engraftment syndrome following hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Bone marrow transplantation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

7 January 2021

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

7 January 2021

Engraftment syndrome after autologous peripheral blood stem cell transplantation with high numbers of peripheral blood stem cells followed by granulocyte colony-stimulating factor administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

7 January 2021

Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703324

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703324

1 reference

Dimensions Publication ID

21 September 2017

0 references

1 reference